Merck KGaA Exercises Third Option in its Immuno-Oncology Collaboration with F- star

 Merck KGaA Exercises Third Option in its Immuno-Oncology Collaboration with F- star

Merck KGaA Exercises Third Option in its Immuno-Oncology Collaboration with F- star

Shots:

  • F-star to receive option exercise payment and will be eligible to get milestones and royalties on net sales of therapies resulting from the collaboration
  • Merck KGaA exercises its third option to develop an additional bispecific program under the ongoing collaboration with F-star
  • Merck KGaA will be responsible for the development and commercialization of the preclinical program. In 2019, the companies collaborated with the first option to license while in July’2020, Merck KGaA brought the second program from the collaboration into its pipeline

Click here to­ read full press release/ article | Ref: GlobeNewswire | Image: PRNewswire

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post